Tenax Secures Oral Levosimendan Supply, Extends Regulatory Deadline to 2035
TENX has more than doubled off its 52-week low of $5.66.
Summary
Tenax Therapeutics has secured a long-term supply agreement for its oral levosimendan product and extended its U.S. regulatory approval deadline to 2035, significantly de-risking its product development.
Key Events · Product Development and Regulatory · TENX
-
Supply Agreement for Oral Levosimendan
Tenax entered a Supply Agreement with Orion Corporation for the manufacture and supply of its orally administered levosimendan product, with Orion designated as the primary supplier. This agreement covers forecasting, ordering, delivery, quality, pricing, and cost-sharing for manufacturing scale-up.
-
Regulatory Approval Deadline Extended
The Sixth Amendment to the License Agreement with Orion extends the date by which regulatory approval for the product must be obtained in the United States to December 31, 2035. This extension removes a key milestone-based termination right for either party.
-
Long-Term Partnership Solidified
The Supply Agreement has an initial term of five years from the first product delivery, with automatic three-year renewals, establishing a long-term manufacturing and supply partnership for a critical product.
Analysis · TENX · Life Sciences
This 8-K details two critical agreements with Orion Corporation. The Supply Agreement secures the manufacturing and supply chain for Tenax's orally administered levosimendan product, a key asset. Concurrently, the Sixth Amendment to their License Agreement extends the regulatory approval deadline in the U.S. to December 31, 2035. This significant extension provides the company with ample time to navigate clinical trials and regulatory processes, substantially reducing a major time-based risk for their product's path to market.
How filings like this one have moved
In the 30 days to Oct 31, 2026, 39.9% of the 1148 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.36%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, TENX was trading at $14.27 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $385.9M. The 52-week trading range was $5.66 to $18.38. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.